Meta AnalysisID 7694
每日两次与每日三次预防性普通肝素给药对住院患者静脉血栓栓塞发生率的系统评价
CRD42023493327
How does three times daily dosing of subcutaneous unfractionated heparin for venous thromboembolism prophylaxis in hospitalized adult patients compare to twice daily dosing relative to the occurrence of venous thromboemb
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7694
- Evidence Id
- 16252
- Core Evidence Id
- 16252
- Source Meta Analysis Id
- 7688
- Herb2 Meta Analysis Id
- HBMA007688
- Crd Id
- CRD42023493327
- Title
- Systematic review of venous thromboembolism occurrence in hospitalized patients following twice vs three times daily prophylactic unfractionated heparin dosing
- Review Question
- How does three times daily dosing of subcutaneous unfractionated heparin for venous thromboembolism prophylaxis in hospitalized adult patients compare to twice daily dosing relative to the occurrence of venous thromboembolism, any bleeding, and heparin-induced thrombocytopenia?
- Study Type Included
- We will include studies that contain one or both dosing regimens of prophylactic unfractionated heparin and objective assessments of any venous thromboembolism. We will exclude case reviews, case series, review articles, commentaries, editorials, and letters, but their reference lists will be examined to identify potentially relevant studies. Non-English articles, non-human studies, and unpublished data will also be excluded.
- Condition Being Studied
- Venous thromboembolism prophylaxis in medically-ill hospitalized patients
- Participant
- Inclusion criteria: • Acute medically ill hospitalized adults (>/=18 years old) on general medical floors requiring venous thromboembolism prophylaxis with subcutaneous unfractionated heparin twice or three times daily Exclusion criteria: • Pregnant patients • Pediatric patients (<18 years old) • All surgery patients • Critical care patients • Trauma patients • COVID-19 patients • Malignancy patients • Patients with extremes of weight <18 BMI or >40 BMI
- Animal
- Human Disease Modelled
- Intervention
- Subcutaneous unfractionated heparin 5000 units three times daily
- Comparator Control
- Subcutaneous unfractionated heparin 5000 units two times daily
- Main Outcome
- Primary outcome: Occurrence of any venous thromboembolism during the inpatient stay while receiving inpatient unfractionated heparin prophylactic therapy. Venous thromboembolism includes a diagnosis of either deep vein thrombosis (DVT) or pulmonary embolism (PE) with an objective assessment. Objective assessments of deep vein thrombosis include duplex ultrasonography, or contrast venography. Objective assessments of pulmonary embolism include computed tomographic pulmonary angiography (CTPA), ventilation-perfusion (V/Q) scan, pulmonary angiography, or magnetic resonance imaging (MRI).
- Outcome Measure
- Additional Outcome
- Safety outcome: Any study reported bleeding during the inpatient stay while receiving inpatient unfractionated heparin prophylactic therapy will be considered a safety outcome. Where possible, events will be classified by major bleeding as defined by the International Society on Thrombosis and Hemostasis (ISTH) major bleeding in non-surgical patients definition as a secondary analysis of the bleeding events. Safety outcome: Any study reported diagnosis of heparin-induced thrombocytopenia (HIT) during the inpatient stay while receiving inpatient unfractionated heparin prophylactic therapy will be considered a safety outcome.
- Study Method
- Prevention, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Maya Chilbert [email protected]
- Organisational Affiliation
- University at Buffalo School of Pharmacy and Pharmaceutical Sciences https://pharmacy.buffalo.edu/
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-12-14
- Registration Date
- 2023-12-25
- Anticipated Start Date
- 2023-12-13
- Anticipated Completion Date
- 2025-06-01
- Title Cn
- 每日两次与每日三次预防性普通肝素给药对住院患者静脉血栓栓塞发生率的系统评价
- Title En
- Systematic review of venous thromboembolism occurrence in hospitalized patients following twice vs three times daily prophylactic unfractionated heparin dosing
- Bilingual Status
- complete